OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab

Despite the recent emergence of targeted therapeutic options, there are still unmet needs concerning moderate-to-severe atopic dermatitis treatment. This review aims to discuss the OX40-OX40L pathway as a therapeutic target for the treatment of atopic dermatitis. OX40 and OX40L are two checkpoint mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lé, Ana Maria, Torres, Tiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787630/
https://www.ncbi.nlm.nih.gov/pubmed/36559247
http://dx.doi.org/10.3390/pharmaceutics14122753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787630/
https://www.ncbi.nlm.nih.gov/pubmed/36559247
http://dx.doi.org/10.3390/pharmaceutics14122753

Ejemplares similares